Latest Market Data
Refresh
Market Turnover
-






-
-
|
|
|
|
|
|
-
-
-
Loading

PEGBIO CO., LTD. - B - H SHARES (2565)

PEGBIO CO-B (2565)

HK$N/A

- (-)

Prev. Close is the most recent non-zero closing value or settlement price.PREV. CLOSE
HK$15.480
Open price is the first traded price of the day. The opening price is reported after 09:20:00 HKT.OPEN
-
TURNOVER
-
VOLUME
-
MKT CAP
HK$4.32B
LOT SIZE
500
BID
-
ASK
-
EPS
-
P/E
-
DIV YIELD
-
INTRA-DAY 52W
High - HK$15.620
Low - HK$8.680
Information is available after the market opens and is delayed by at least 15 minutes.
Updated: 24 Jul 2025
  • 1 D
  • 1 M
  • 3 M
  • 6 M
  • YTD
  • 1 Y
  • 2 Y
  • 5 Y
  • 10 Y
1min
5min
15min
Hourly
Created with Highstock 6.2.0No Data AvailableNaN10:0011:0012:0013:0014:0015:0016:0015.44015.46015.48015.50015.520Prev. Close
15.480
All charts use the last traded price or closing price.

COMPANY PROFILE

PegBio Co Ltd is a China-based company primarily engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia). *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares) 279,164,339 (as at 30 Jun 2025)
Industry Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Listing Date 27 May 2025
Financial Year Ends -
Chairman Michael Min Xu
Principal Office Room 606, Building 1
Haozhang Tower
Gongshu District, Hangzhou
Zhejiang Province, PRC
Place of Incorporation PRC
Listing Category Primary Listing

a. Updating time-lag
The number of issued shares / issued units presented is generally updated within 7 days after the Monthly Returns and Next Day Disclosure Returns published by the listed issuers on the HKEXnews website. Hence, the information presented here may not be the most up-to-date information submitted by the listed issuers as required under the Listing Rules.
b. Rights issues or bonus issues
The number of issued shares / issued units presented here will be adjusted with effect from the ex-date in the event of announced rights issues or announced bonus issues. In this case, both the number of issued shares / issued units before and after the adjustment will be presented.
c. Share splits or share consolidations
The number of issued shares / issued units presented here will be adjusted on the effective date in the event of share splits or share consolidations.
d. Conversion of convertible notes into shares
If the change of the number of issued shares / issued units is due to conversion of convertible bonds, the number of issued shares / issued units presented here may be updated based on the related company announcement.
Updated: 24 Jul 2025 18:24 HKT
* Company profile is provided by Refinitiv.

ENTITLEMENT

Date Announced Ex-Date Details Financial Year End Book Close Date Payment date may be indicative only.Payment Date
Updated:
Dividend details are sourced from Announcement Forms published on HKEXnews